With your heightened risk of Parkinsons post stroke, now your competent? doctor can determine if those Parkinson prevention protocols, they created 8 years ago actually work. Oh no, your doctor didn’t create those prevention protocols? What were they thinking? Oh, not thinking at all about the sequalae of stroke! So, they were and are FUCKING INCOMPETENT!
I guess you’ll have to read up on prevention yourself! I’m mainly doing coffee.
(77 posts to August 2014)
New Biomarker Enables Early, Accurate Diagnosis of Parkinson’s
Summary: Researchers have identified a biomarker in
spinal fluid that can detect Parkinson’s disease in its early stages
with over 90% accuracy. Using a patented immuno-infrared sensor (iRS)
technology, they measured the misfolding of the alpha-synuclein (αSyn)
protein, a key driver of the disease.
Early diagnosis is crucial,
as clinical symptoms usually appear only after severe and irreversible
brain damage. Beyond diagnosis, the platform could also accelerate the
development and validation of new Parkinson’s therapies.
Key Facts:
- Early Detection: Misfolded alpha-synuclein (αSyn) in spinal fluid predicts Parkinson’s with over 90% sensitivity and specificity.
- Advanced Technology: The iRS platform detects protein misfolding, a method also validated in Alzheimer’s diagnostics.
- Therapeutic Potential: The biomarker may aid in developing and testing new Parkinson’s treatments by monitoring disease progression.
Source: RUB
Parkinson’s
disease is a neurodegenerative disorder that is usually diagnosed in
its late stage on the basis of clinical symptoms, mainly motor
disorders.
By this point, however, the brain is already severely and irreparably
damaged. Moreover, diagnosis is difficult and often incorrect because
the disease takes many forms and symptoms overlap with other disorders.
Researchers
from the PRODI Center for Protein Diagnostics at Ruhr University
Bochum, Germany, and the biotech company betaSENSE have now discovered a
biomarker in the spinal fluid that facilitates a reliable diagnosis at
an early stage and can shed light on the progression of the disease and
the effect of a therapy.
They report their findings in the journal EMBO Molecular Medicine on April 25, 2025.
Parkinson’s disease – an unstoppable condition
Parkinson’s
disease is characterized by the loss of dopaminergic nerve cells in the
brain, which usually leads to increasing motor impairments as the
symptoms progress. Dopamine supplements can compensate for the loss and
temporarily alleviate the symptoms.
The misfolding of the key
protein alpha-synuclein (αSyn) from α-helical structures to β-sheet-rich
structures plays a crucial role in the development of Parkinson’s
disease.
“These misfoldings make the protein sticky, leading to
the formation of larger complexes, so-called oligomers. The oligomers
then produce long fibrillar filaments and cause the aggregation of these
filaments into macroscopically large Lewy bodies in the brain,”
explains Professor Klaus Gerwert, founding and managing director at
PRODI and CEO of betaSENSE.
Advanced platform technology
In
two independent clinical cohorts with a total of 134 participants, the
Bochum-based researchers showed that, with a sensitivity and specificity
of well over 90 percent, this misfolding of αSyn in body-fluids is a
viable biomarker for the diagnosis of Parkinson’s disease.
The
research was conducted using cerebrospinal fluid samples from patients
at the Parkinson’s centers in Bochum (St. Josef Hospital, Professor Lars
Tönges, Professor Ralf Gold) and Kassel (Paracelsus-Elena-Klinik, Dr.
Sandrina Weber, Professor Brit Mollenhauer).
The measurements were carried out using the patented iRS (immuno-infrared sensor) technology from betaSENSE GmbH.
betaSENSE
has already successfully implemented the iRS technology for diagnosing
Alzheimer’s disease. In this case, it was shown that the misfolding of
the biomarker Aβ can indicate the risk of Alzheimer’s dementia at a
later stage with high accuracy up to 17 years before clinical diagnosis.
“We have now transferred this approach to Parkinson’s for the misfolding of αSyn,” stresses Klaus Gerwert.
Development of Parkinson’s drugs
In addition to diagnostic applications, the technology can also help
to develop new active substances and prove their efficacy in clinical
trials.
About this Parkinson’s disease research news
Author: Julia Weiler
Source: RUB
Contact: Julia Weiler – RUB
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Alpha-synuclein Misfolding as Fluid Biomarker for Parkinson’s Disease Measured with the iRS Platform” by Klaus Gerwert et al. EMBO Molecular Medicine
